Osteonecrosis of the jaws in patients treated with bisphosphonates

Journal of Clinical and Experimental Dentistry

Volumn 4, Issue 1, 2012, Pages 60-65

  Ata Ali, Fadi ^a   Ata Ali, Javier ^a,b   Flichy Fernández, Antonio Juan ^a   Bagán, José Vicente ^c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Valencian public healthcare service   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Bisphosphonates; Etiopathogenesis; Osteonecrosis of the jaws; Prevention; Treatment

Indexed keywords

EID: 84865064246     PISSN: None     EISSN: 19895488     Source Type: Journal    
DOI: 10.4317/jced.50649     Document Type: Review

References (40)

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.
2. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg. 2009;67:2-12.
3. Bittner T, Lorbeer N, Reuther T, Böhm H, Kübler AC, Müller-Richter UD. Hemimandibulectomy after bisphosphonate treatment for complex regional pain syndrome: A case report and review on the prevention and treatment of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Mar 30. [Epub ahead of print].
4. Borromeo GL, Tsao CE, Darby IB, Ebeling PR. A review of the clinical implications of bisphosphonates in dentistry. Aust Dent J. 2011;56:2-9.
5. Gupta S, Jain P, Kumar P, Parikh PM. Zoledronic acid induced osteonecrosis of tibia and femur. Indian J Cancer. 2009;46:249-250.
6. Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, et al. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci. 2011;1218:62-79.
7. Hoefert S, Eufinger H. Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg. 2011;69:362-80.
8. Bagán JV, Diz-Dios P, Gallego L, Infante-Cossío P, Jiménez Y, Junquera LM, et al. Recomendaciones para la prevención de la osteonecrosis de los maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos intravenosos. Med Oral Patol Oral Cir Bucal. 2008;13:161-7.
9. Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg. 2011;40:277-84.
10. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010;28:365-83.
11. Narongroeknawin P, Danila MI, Humphreys LG Jr, Barasch A, Curtis JR. Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dentist. 2010;30:77-82.
12. Pautke C, Bauer F, Otto S, Tischer T, Steiner T, Weitz J, et al. Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. J Oral Maxillofac Surg. 2011;69:84-91.
13. Ferlito S, Puzzo S, Liardo C. Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. J Oral Maxillofac Surg. 2011;69:e1-4.
14. Wutzl A, Pohl S, Sulzbacher I, Seemann R, Lauer G, Ewers R, et al. Factors influencing surgical treatment of bisphosphonate- related osteonecrosis of the jaws. Head Neck. 2011 Mar 11. [Epub ahead of print]
15. Maurer P, Sandulescu T, Kriwalsky MS, Rashad A, Hollstein S, Stricker I, et al. Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris. Int J Oral Maxillofac Surg. 2011;40:285-91.
16. Scoletta M, Arduino PG, Pol R, Arata V, Silvestri S, Chiecchio A, et al. Initial experience on the outcome of teeth extractions in intravenous bisphosphonate-treated patients: a cautionary report. J Oral Maxillofac Surg. 2011;69:456-62.
17. Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncol. 2009;45:551-4.
18. Reid IR, Cundy T. Osteonecrosis of the jaw. Skeletal Radiol. 2009;38:5-9.
19. Kim RH, Lee RS, Williams D, Bae S, Woo J, Lieberman M, et al. Bisphosphonates Induce Senescence in Normal Human Oral Keratinocytes. J Dent Res. 2011 Mar 22. [Epub ahead of print].
20. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg 2010;68:959-63.
21. Feller L, Wood NH, Raubenheimer EJ, Meyerov R, Lemmer J. Alveolar bone necrosis and spontaneous tooth exfoliation in an HIV- seropositive subject with herpes zoster. SADJ 2008;63:106-10.
22. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397- 410.
23. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg. 2008;66:223-30.
24. Fugazzotto PA, Lightfoot WS, Jaffin R, Kumar A. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow- up, and the incidence of complications in two private practices. J Periodontol. 2007;78:1664-9
25. Shirota T, Nakamura A, Matsui Y, Hatori M, Nakamura M, Shintani S. Bisphosphonate-related osteonecrosis of the jaw around dental implants in the maxilla: report of a case. Clin Oral Implants Res. 2009;20:1402-8.
26. Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 2006;42:327-9.
27. Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study. Oral Oncol. 2011;47:185-90.
28. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120-3.
29. Morag Y, Morag-Hezroni M, Jamadar DA, Ward BB, Jacobson JA, Zwetchkenbaum SR, et al. Bisphosphonate-related osteonecrosis of the jaw: a pictorial review. Radiographics. 2009;29:1971-84.
30. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433-41.
31. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci. 2011;1218:38-46.
32. Bagan JV, Jimenez Y, Diaz JM, Murillo J, Sanchis JM, Poveda R, et al. Osteonecrosis of the jaws in intravenous bisphosphonate use: Proposal for a modification of the clinical classification. Oral Oncol. 2009;45:645-6.
33. Woo SB, Mawardi H, Treister N. Comments on "Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification". Oral Oncol. 2009;45:740.
34. Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12:E336-40.
35. Marcuzzi A, Zanin V, Crovella S, Pontillo A. Comments on '"Geranylgeraniol - A new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw" by Ziebart T et al.(2011). Oral Oncol. 2011;47:436-7.
36. Bocanegra-Pérez S, Vicente-Barrero M, Sosa-Hernández M, Knezevic M, Castellano-Navarro JM, Rodríguez-Millares J. Bisphosphonateassociated osteonecrosis of the jaw. A proposal for conservative treatment. Med Oral Patol Oral Cir Bucal. 2008;13:E770-3.
37. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-75.
38. Tirelli G, Biasotto M, Chiandussi S, Dore F, De Nardi E, Di Lenarda R. Bisphosphonate-associated osteonecrosis of the jaws: The limits of a conservative approach. Head Neck. 2009; 31:1249.
39. Bagan JV, Jiménez Y, Gómez D, Sirera R, Poveda R, Scully C. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol. 2008;44:1088-9.
40. Kwon YD, Ohe JY, Kim DY, Chung DJ, Park YD. Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? Clin Oral Implants Res. 2011;22:100-5.